{
    "clinical_study": {
        "@rank": "26669", 
        "arm_group": [
            {
                "arm_group_label": "Fenobam 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule."
            }, 
            {
                "arm_group_label": "Fenobam 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule."
            }, 
            {
                "arm_group_label": "Fenobam 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule."
            }, 
            {
                "arm_group_label": "Placebo arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, blinded, parallel group, placebo-controlled trial on 32 evaluable\n      healthy male and non-pregnant female, 18-50 year old volunteers.  The investigators goal is\n      to observe the pharmacokinetics of fenobam after oral administration of 50, 100 or 150 mg in\n      groups of healthy individuals and to compare the side effects and tolerability of a single\n      dose of fenobam with placebo."
        }, 
        "brief_title": "Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine)\n      urea hydrate], oral administration of one 50 mg gelatin capsule.\n\n      Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.\n\n      Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.\n\n      Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. 18-50 yr old\n\n          2. Good general health with no remarkable medical conditions (e.g  liver, kidney, heart,\n             or lung failure), BMI<33 and no known drug allergies.\n\n          3. Willing to comply with study guidelines as outlined in protocol\n\n          4. Willing to provide informed consent.\n\n        Exclusion Criteria\n\n          1. Medication use (prescription or non prescription medications, vitamins, herbals,\n             dietary and mineral supplements and grapefruit products during or within 14 days\n             prior to study participation; excludes contraceptives)\n\n          2. History of addiction to drugs or alcohol (prior or present addiction or treatment for\n             addiction)\n\n          3. Pregnant or nursing female\n\n          4. Lactose intolerance\n\n          5. Smokers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806415", 
            "org_study_id": "201304126"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Fenobam 50 mg", 
                    "Fenobam 100 mg", 
                    "Fenobam 150 mg"
                ], 
                "description": "Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)", 
                "intervention_name": "Fenobam", 
                "intervention_type": "Drug", 
                "other_name": "N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea"
            }, 
            {
                "arm_group_label": "Placebo arm", 
                "description": "Oral administration of placebo or lactose 150 mg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Lactose"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fenobam,", 
            "Pharmacokinetics", 
            "side effects"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School Of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double Blind, Randomized, Single Dose, Placebo Controlled Study of the Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Laura Cavallone, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Blood samples will be drawn periodically before and after fenobam/placebo administration for approximately 10 hours (at approximately 30, 60, 120, 180, 240, 300, 360 and 600 minutes) and one more time the next day (day 2).", 
            "measure": "Pharmacokinetic data after oral administration of 50, 100 or 150 mg of fenobam in groups of healthy individuals.", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806415"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Washington University School of Medicine", 
            "investigator_full_name": "Laura Cavallone", 
            "investigator_title": "Assistant Professor of Anesthesiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participants will be administered a questionnaire regarding side effects at the end of the study day, after administration of a single dose of 50 mg, 100 mg or 150 mg of fenobam, or 150 mg placebo. The questionnaire will be administered again the following day and one week after the study day. Side effects in the fenobam treatment groups will be compared to side effects in the placebo group.", 
            "measure": "Number of participants with adverse events as a measure of tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "1 week"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}